Core Insights - The Zacks Equity Research team has highlighted several stocks, including AbbVie Inc., The Coca-Cola Co., Chevron Corp., ImmuCell Corp., and Precipio, Inc., in their Analyst Blog [1][2]. AbbVie Inc. (ABBV) - AbbVie has outperformed the Zacks Large Cap Pharmaceuticals industry over the past year, with a share price increase of +31.6% compared to the industry’s +19.5% [4]. - The company has successfully managed the loss of exclusivity for Humira by launching new immunology drugs, Skyrizi and Rinvoq, which are performing well and expected to support revenue growth [4][5]. - AbbVie is returning to robust revenue growth in 2025, following the U.S. Humira loss of exclusivity, and has been actively acquiring companies to enhance its early-stage pipeline [5]. The Coca-Cola Co. (KO) - Coca-Cola's shares have outperformed the Zacks Beverages - Soft Drinks industry over the past year, with a gain of +14.5% compared to +10.5% for the industry [6]. - The company's performance is attributed to solid organic revenue growth, effective pricing strategies, and gains in global market share within the non-alcoholic ready-to-drink category [6][7]. - Ongoing innovation and digital transformation efforts are enhancing Coca-Cola's competitive edge, although the company faces challenges such as soft volumes in key regions and currency headwinds [7][8]. Chevron Corp. (CVX) - Chevron's shares have increased by +9.5% over the past year, while the Zacks Oil and Gas - Integrated - International industry has gained +16% [9]. - The acquisition of Hess has significantly improved Chevron's growth outlook by adding high-quality assets in regions like Guyana and the Gulf of Mexico [9]. - The Permian Basin remains a key asset for Chevron, driving consistent growth, although challenges such as lower crude realizations and regulatory issues in California temper optimism [10]. ImmuCell Corp. (ICCC) - ImmuCell has outperformed the Zacks Medical - Products industry with a share price increase of +26.3% compared to +1% for the industry [11]. - The company’s First Defense franchise leads the market in calf scours prevention, with Tri-Shield accounting for 70% of volume and a 48% market share [11][12]. - ImmuCell has resolved operational bottlenecks, restoring capacity to $30 million in annual sales, with TTM revenues of $27.8 million, reflecting a 16% year-over-year increase [12][13]. Precipio, Inc. (PRPO) - Precipio's shares have surged by +361.2% over the past year, significantly outperforming the Zacks Medical Info Systems industry, which saw a decline of -1.3% [14]. - The company is moving towards self-funded growth, driven by its Pathology Services division, which is experiencing steady organic growth and rising margins [14][15]. - Precipio has improved profitability and cash flow, although it faces risks related to liquidity and regulatory uncertainties [15][16].

Core Insights - Precipio, Inc. is set to present findings from a joint study with Memorial Sloan Kettering Cancer Center, highlighting the positive impacts of its BCR::ABL1 assay on patient care [1][2] Group 1: Study Findings - The comprehensive study involved 895 patient samples and demonstrated superior performance of the BCR::ABL1 assay, showing concordance with two other leading platforms [2] - The study indicates clear, positive impacts on patient care and significant improvements in laboratory workflows [2] Group 2: Company Overview - Precipio is a healthcare biotechnology company focused on cancer diagnostics, aiming to address cancer misdiagnoses through innovative diagnostic products and services [3] - The company's mission includes delivering higher accuracy and improved laboratory workflow, ultimately leading to better patient outcomes and reduced healthcare expenses [3]

NEW HAVEN, Conn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Precipio, Inc. reports that the Company recently identified a single, limited scope unauthorized access to a specific data folder stored within its secure cloud file environment. The incident was limited to its file storage server and did not impact any of Precipio’s operations, diagnostics processes, or customer services, and the company continued to provide its services unhindered. There was no impact to patient care; nor impact to the company’s operatio ...

Core Viewpoint - Precipio, Inc. (PRPO) has demonstrated significant financial improvement in Q3 2025, with strong revenue growth and operational momentum, leading to a notable increase in stock performance compared to the broader market [1][2]. Financial Performance - Revenue for Q3 2025 increased by 29.9% year over year to $6.8 million from $5.2 million, and sequentially rose by 19.7% from $5.7 million in Q2 2025 [2]. - Adjusted EBITDA improved to $0.5 million from $0.1 million a year ago and from a loss of $0.1 million in the prior quarter [2][4]. - Gross margin increased to 44% from 43% in Q2 2025, while GAAP net loss narrowed to $0.1 million from $0.6 million in Q3 2024 [2]. Segment Performance - The Pathology Services division saw a 20% sequential revenue increase to $6 million, driven by new customer additions [3]. - The Products division experienced a 16% sequential revenue growth to $0.7 million, supported by increased orders from existing clients [3]. Operational Metrics - EBITDA reached $0.3 million in Q3 2025, compared to a loss of $0.3 million in the same quarter last year [4]. - Operating cash flow generated was $285,000, a significant improvement from a cash burn of $148,000 in Q2 2025 [4]. Margin Dynamics - Pathology Services gross margin improved from 43% to 46% quarter over quarter, while the Products division margin fell from 44% to 30% due to strategic investments [5][11]. - Management expects that revenue scaling will offset temporary margin pressures from these investments [5]. Management Insights - Management characterized the quarter as a turning point, emphasizing a shift from survival to strategic expansion, with a focus on operational discipline and sustained revenue gains [6]. - The company aims to operate without dependence on external capital, allowing for reinvestment in growth initiatives [6]. Future Outlook - Management outlined four priorities for the remainder of 2025 and into 2026: sustaining double-digit growth, further margin expansion, reinvestment of internally generated cash, and broader investor outreach [12]. - PRPO expects overall company gross margins to exceed 50% by mid-2026 as revenue scales against a largely fixed-cost structure [12]. Other Developments - The company expanded its laboratory space during Q3 2025, incurring an additional $120,000 in annual rent, aimed at increasing operational efficiency [14].

Core Viewpoint - The conference call is focused on providing a shareholder update for Precipio's third quarter of 2025, highlighting forward-looking statements about the company's business performance and expectations [1][3]. Group 1: Forward-Looking Statements - The statements made during the call include forward-looking statements that are based on current expectations, forecasts, and assumptions, which are subject to significant risks and uncertainties [1]. - Forward-looking statements may include terms such as may, will, should, could, expect, intend, plan, anticipate, believe, estimate, predict, potential, forecast, and continue [1]. Group 2: Risks and Uncertainties - Actual results may differ materially from those set forth in forward-looking statements due to various risks and uncertainties [2]. - The company references its annual report on Form 10-K for the year ended December 31, 2024, which details risk factors that could impact results [2].

Financial Data and Key Metrics Changes - The company achieved a positive adjusted EBITDA of nearly $500,000 for the first time in its history, marking a significant milestone [3] - Cash generated from operations was over $250,000, indicating a positive cash flow transformation [3] - Q3 revenue reached $6.8 million, a 30% increase year-over-year and a 20% increase quarter-over-quarter [7] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in the previous quarter [17] - Cash from operations swung positively to $285,000 from a cash burn of $148,000 in the previous quarter, representing a $433,000 improvement [17] Business Line Data and Key Metrics Changes - The Pathology Services Division generated $6 million in Q3, a 20% increase from $5 million in Q2, driven by new customer acquisitions [8] - Gross margin for the Pathology Services Division improved from 43% to 46% due to efficient operations [17] - The Products Division saw a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3 [10] - Overall gross margins improved slightly from 43% to 44%, with expectations for continued upward trends as both divisions grow [11] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance [5] - The company is positioned to leverage its distributor network for scalable growth, indicating a shift in market strategy [11] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated into growth initiatives [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and increasing liquidity and share price appreciation [19] - The company aims to achieve gross margins exceeding 50% by mid-2026 as both divisions build revenues on existing infrastructure [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, indicating no need for outside capital to cover operational costs [18] - The company is optimistic about continued growth and market opportunities as it enhances its operational and financial success [19] - Management highlighted the importance of their mission in improving patient care, emphasizing that growth translates into better treatment outcomes [19] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [18] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [12][15] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the conference call concluded without a Q&A segment [21]

Financial Data and Key Metrics Changes - The company achieved a positive adjusted EBITDA of nearly $500,000 for the first time in its history, marking a significant financial milestone [3] - Cash generated from operations was over $250,000, indicating a shift towards financial independence [3] - Q3 revenue reached $6.8 million, a 30% increase year-over-year and a 20% increase quarter-over-quarter [7] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in the previous quarter [17] - Cash from operations showed a positive swing of $433,000, moving from a cash burn of $148,000 in Q2 to a cash generation of $285,000 in Q3 [17] Business Line Data and Key Metrics Changes - The Pathology Services Division generated $6 million in Q3, a 20% increase from $5 million in Q2, driven by new customer acquisitions [8] - Gross margin for the Pathology Services Division improved from 43% to 46% due to efficient operations [17] - The Products Division saw a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3 [10] - Overall gross margins improved slightly from 43% to 44%, with expectations for continued upward trends as both divisions grow [11] Market Data and Key Metrics Changes - The company’s share price has tripled since the beginning of 2025, reflecting market confidence in its financial performance [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating potential for future growth [8] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated into growth initiatives [3][5] - Plans include driving double-digit growth in both divisions, expanding margins, and increasing liquidity and share price appreciation [19] - The company aims to leverage its financial independence to explore strategic partnerships and innovative products [19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company’s ability to grow organically without reliance on outside capital, marking a significant operational threshold [18] - The focus is on maintaining a culture of accountability, collaboration, and customer empathy to support sustained growth [9] - Future priorities include continued growth, margin expansion, and strategic reinvestment to enhance market position [19] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [18] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [12][15] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the conference call concluded without a Q&A segment [21]

Financial Data and Key Metrics Changes - For Q3 2025, the company achieved a positive adjusted EBITDA of nearly $500,000 and generated over $250,000 in cash from operations, marking a significant financial milestone [3][15] - Revenue for Q3 reached $6.8 million, representing a 30% increase year-over-year and a 20% increase quarter-over-quarter [6] - Adjusted EBITDA improved to $469,000 compared to $100,000 a year ago and a loss of $78,000 in Q2 2025, indicating a swing of over $500,000 in just one quarter [15] - Cash generated from operations was $285,000, a positive cash swing of $433,000 compared to a cash burn of $148,000 in the previous quarter [15] Business Line Data and Key Metrics Changes - The Pathology Services Division reported revenue growth from $5 million in Q2 to $6 million in Q3, a 20% increase, driven by new customer acquisitions [7] - The Products Division experienced a 16% quarter-over-quarter growth, increasing from approximately $620,000 in Q2 to $720,000 in Q3, primarily due to increased utilization from existing customers and new product introductions [9][10] - Gross margins improved from 43% to 44% overall, with the Pathology Services Division increasing margins from 43% to 46% [10][15] Market Data and Key Metrics Changes - The company has seen a tripling of its share price since the beginning of 2023, reflecting market confidence in its financial performance and growth strategy [5] - The company is experiencing a strong sales funnel with several new customers in trial phases, indicating a robust market demand for its services [7] Company Strategy and Development Direction - The company is transitioning from a defensive to an offensive strategy, focusing on reinvesting cash generated from operations to accelerate growth [3][5] - Future priorities include driving double-digit growth in both divisions, expanding margins, and reinvesting cash into growth initiatives [17] - The company aims to achieve a gross margin exceeding 50% by mid-2026 as both divisions scale up [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's self-sustaining business model, stating that it will no longer depend on outside capital for operations [16] - The company anticipates that increased market capitalization will present new strategic opportunities for growth and partnerships [16] - Management emphasized the importance of their mission, linking financial success to improved patient care outcomes [17] Other Important Information - The company is nearing the completion of its full repayment of Change Healthcare, which will free up cash generated from operations starting in Q1 2026 [16] - The company has made strategic investments in lab space and technical support to enhance operational efficiency and customer onboarding [11][14] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Performance - Precipio, Inc. reported Q3-2025 revenues of $6.8 million, representing a 30% year-over-year increase from $5.2 million in Q3-2024 and a 20% quarter-over-quarter increase from $5.7 million in Q2-2025 [10] - Adjusted EBITDA for Q3-2025 was $469,000, up $369,000 year-over-year and over $500,000 from Q2-2025, marking a significant turnaround from negative to positive [10] - Operating cash flow improved from a cash burn of $148,000 in Q2-2025 to a positive cash flow of $285,000 in Q3-2025, indicating a $433,000 swing quarter-over-quarter [10] Pathology Services Division - Revenue in the Pathology Services Division increased by approximately $1.0 million, or 20%, from $5.0 million in Q2-2025 to $6.0 million in Q3-2025, driven by new service initiations [3][10] - Gross margins for the Pathology Services Division improved from 43% to 46% quarter-over-quarter, supported by past investments in capacity [7] Products Division - The Products Division saw a revenue increase of 16% quarter-over-quarter, rising from $620,000 in Q2-2025 to $720,000 in Q3-2025, primarily due to existing customers ordering more products [5][10] - Gross margins for the Products Division decreased from 44% in Q2-2025 to 30% in Q3-2025, attributed to investments made to prepare for growth [8] Future Outlook - The company anticipates continued gross margin increases towards the 50% mark as the Pathology business leverages economies of scale and the Products Division builds more revenue [9] - Management expressed confidence in seizing growth opportunities created by the recent financial performance and operational efficiencies [3]

Financial Performance - Net sales for the three months ended September 30, 2025, were approximately $6.8 million, an increase of $1.5 million or 30% compared to the same period in 2024[149] - Net sales for the nine months ended September 30, 2025, were approximately $17.4 million, an increase of $4.3 million or 33% compared to the same period in 2024[154] - Gross profit for the three months ended September 30, 2025, was approximately $3.0 million, an increase of $0.7 million or 41% compared to the prior year period[151] - Gross profit for the nine months ended September 30, 2025, was approximately $7.6 million, representing a 73% increase from $4.9 million in 2024, with a gross margin of 44% compared to 38% in 2024[156] Revenue Sources - Patient diagnostic service revenue increased by $1.5 million due to a 19% increase in cases processed, totaling 4,258 cases in Q3 2025 compared to 3,584 cases in Q3 2024[149] - Patient diagnostic service revenue increased by $4.2 million, driven by a 25% increase in processed cases, totaling 10,971 cases in 2025 compared to 8,745 cases in 2024[154] Operating Expenses - Operating expenses increased by $0.2 million for the three months ended September 30, 2025, primarily due to increased personnel costs and recruiting expenses[152] - Operating expenses increased by $0.5 million for the nine months ended September 30, 2025, with general and administrative expenses rising by $0.3 million primarily due to personnel costs[157][158] Loss and Deficit - The company incurred an operating loss of $1.7 million for the nine months ended September 30, 2025, with an accumulated deficit of $103.3 million[146] Other Income and Funding - The company recorded approximately $0.9 million of other income due to non-recurring items, including a $0.8 million Employee Retention Credit refund[145] - The company received approximately $1.1 million from Change Healthcare through a Temporary Funding Assistance Program following a cybersecurity breach[139] - The company recorded net other income of $0.9 million for the nine months ended September 30, 2025, compared to a net other expense of $45,000 in 2024[159] Cash Flow and Working Capital - Working capital improved to $1.2 million as of September 30, 2025, an increase of $2.0 million from a negative working capital of $820,000 at the end of 2024[160] - Cash flows provided by operating activities were $0.3 million for the nine months ended September 30, 2025, compared to cash used in operating activities of $0.1 million in 2024[161] - Cash flows used in investing activities were approximately $0.3 million for the nine months ended September 30, 2025, resulting from purchases of property and equipment[162] - Cash flows provided by financing activities totaled $0.8 million for the nine months ended September 30, 2025, including $1.3 million from the exercise of warrants[163] Commitments and Assessments - The company has 31,944 outstanding warrants as of September 30, 2025, with proceeds of approximately $1.3 million received from the exercise of 100,000 warrants during the three months ended September 30, 2025[147] - The company is assessing the impact of the One Big Beautiful Bill Act of 2025 on its business and financial statements[148] - The company had off-balance sheet purchase commitments of approximately $1.9 million as of September 30, 2025, primarily for laboratory reagents[167]